Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832946 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Galecto Biotech AB.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
NCT03832946 is a Phase 2 study that has completed, run by Galecto Biotech AB. The registered enrollment target is 172 participants.
The verdict
NCT03832946, a Phase 2 study, has completed, sponsored by Galecto Biotech AB.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
Interventions
- DRUG Placebo
- DRUG GB0139
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03832946
The ClinicalTrials.gov registry entry for NCT03832946 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galecto Biotech AB, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03832946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03832946 about?
NCT03832946 is a clinical study titled "A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)". This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
What is the current status of trial NCT03832946?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2019-02-19. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT03832946?
The interventions under investigation include: Placebo (DRUG), GB0139 (DRUG).
Who is sponsoring clinical trial NCT03832946?
This trial is sponsored by Galecto Biotech AB, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.